Johnson & Johnson Upgraded to 'Neutral'

Johnson & Johnson
Johnson & Johnson

Health care company Johnson & Johnson got a ratings upgrade to "neutral."

Catherine Arnold, senior pharmaceuticals analyst at Credit Suisse, told “Closing Bell” why her firm lifted the company from underperform -- but is still holding off from an "overperform" rating.

“Growth expectations were overstated for J&J in regards to two of its key franchises: schizophrenia and anemia,” said Arnold.

But, she added, “We think that recently, investor expectations have become more realistic on those two. So we feel more comfortable that there’s less risk to the downside on Johnson & Johnson.”

“If you think in terms of free cash flow they’re strong,” said Arnold. “If you think about debt load, they’re very attractive. But it’s the growth issue that prevents us from having a more bullish point of view on this stock.”

She recommended Schering Plough as one of her favorite picks.

Contact Closing Bell

  • Showtimes

    United States
    Monday - Friday 3:00P ET
    Monday - Saturday 21:00 CET
    Tuesday - Saturday 03:00 SIN/HK
    Tuesday - Saturday 05:00 SYD
    New Zealand
    Tuesday - Saturday 07:00 NZ
  • Bill Griffeth

    With almost 30 years experience in business television, Bill Griffeth is co-anchor of the 3 p.m. ET hour of CNBC's "Closing Bell."

  • Kelly Evans

    Kelly Evans is co-anchor of CNBC's "Closing Bell."